+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

4D Molecular Therapeutics Inc (FDMT) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 53 Pages
  • May 2026
  • GlobalData
  • ID: 5960491
4D Molecular Therapeutics Inc (FDMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

4D Molecular Therapeutics Inc (4DMT) is a clinical-stage biopharmaceutical company focused on developing genetic medicines to treat large-market diseases. The company’s therapy areas include ophthalmology, pulmonology, and cardiology. It utilizes the proprietary therapeutic vector evolution platform to create customised gene delivery vectors for targeted therapeutic applications. 4DMT's major products include clinical-stage candidates such as the 4D-150 for the treatment of wet AMD and DME through late-stage studies and 4D-710 for the treatment of cystic fibrosis. Its other pipeline products include 4D-175 for the treatment of geographic atrophy, 4D-725 for the treatment of alpha-1 antitrypsin deficiency, and 4D-310 for the treatment of Fabry disease cardiomyopathy. The company operates its research, development, and manufacturing facility in the US. 4DMT is headquartered in Emeryville, California, the US.

4D Molecular Therapeutics Inc Key Recent Developments

  • Mar 16, 2026: 4DMT to Participate in Upcoming Investor Meetings
  • Feb 19, 2026: 4DMT to Participate in Upcoming Investor Conferences
  • Jan 07, 2026: 4DMT Provides Company Update and Development Milestones for 2026
  • Dec 08, 2025: 4DMT to Present at 44th Annual J.P. Morgan Healthcare Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • 4D Molecular Therapeutics Inc - Key Facts
  • 4D Molecular Therapeutics Inc - Key Employees
  • 4D Molecular Therapeutics Inc - Key Employee Biographies
  • 4D Molecular Therapeutics Inc - Major Products and Services
  • 4D Molecular Therapeutics Inc - History
  • 4D Molecular Therapeutics Inc - Company Statement
  • 4D Molecular Therapeutics Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • 4D Molecular Therapeutics Inc - Business Description
  • R&D Overview
  • 4D Molecular Therapeutics Inc - Corporate Strategy
  • 4D Molecular Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • 4D Molecular Therapeutics Inc - Strengths
  • 4D Molecular Therapeutics Inc - Weaknesses
  • 4D Molecular Therapeutics Inc - Opportunities
  • 4D Molecular Therapeutics Inc - Threats
  • 4D Molecular Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • 4D Molecular Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • 4D Molecular Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • 4D Molecular Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 16, 2026: 4DMT to Participate in Upcoming Investor Meetings
  • Feb 19, 2026: 4DMT to Participate in Upcoming Investor Conferences
  • Jan 07, 2026: 4DMT Provides Company Update and Development Milestones for 2026
  • Dec 08, 2025: 4DMT to Present at 44th Annual J.P. Morgan Healthcare Conference
  • Nov 17, 2025: 4DMT Appoints Kristian Humer As Chief Financial Officer
  • Nov 10, 2025: 4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
  • Nov 06, 2025: 4DMT to Participate in Jefferies 2025 London Healthcare Conference
  • Oct 31, 2025: Otsuka Enters Licensing Agreement for Ophthalmic Gene Therapy Drug Candidate 4D-150
  • Oct 31, 2025: Otsuka Pharmaceutical Licenses Gene Therapy For Eye Diseases From 4DMT
  • Oct 30, 2025: 4DMT Enters License Agreement with Otsuka Pharmaceutical for 4D-150 in Asia-Pacific
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • 4D Molecular Therapeutics Inc, Key Facts
  • 4D Molecular Therapeutics Inc, Key Employees
  • 4D Molecular Therapeutics Inc, Key Employee Biographies
  • 4D Molecular Therapeutics Inc, Major Products and Services
  • 4D Molecular Therapeutics Inc, History
  • 4D Molecular Therapeutics Inc, Key Competitors
  • 4D Molecular Therapeutics Inc, Ratios based on current share price
  • 4D Molecular Therapeutics Inc, Annual Ratios
  • 4D Molecular Therapeutics Inc, Interim Ratios
  • 4D Molecular Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • 4D Molecular Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • 4D Molecular Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • 4D Molecular Therapeutics Inc, Performance Chart (2021-2025)
  • 4D Molecular Therapeutics Inc, Ratio Charts
  • 4D Molecular Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • 4D Molecular Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sanofi Genzyme US
  • Ocular Therapeutix Inc
  • EyePoint Inc
  • Takeda Pharmaceutical Co Ltd
  • Spirovant Sciences Ltd
  • Roche Holding AG
  • Kodiak Sciences Inc
  • Amicus Therapeutics Inc
  • REGENXBIO Inc
  • Regeneron Pharmaceuticals Inc
  • Vertex Pharmaceuticals Inc
  • Sionna Therapeutics Inc
  • Adverum Biotechnologies Inc
  • AbbVie Inc
  • Apellis Pharmaceuticals Inc
  • Recode Therapeutics Inc
  • Krystal Biotech Inc
  • Arcturus Therapeutics Holdings Inc